BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

...the academic work of co-founder Moin Saleem, a professor of pediatric renal medicine at the University of Bristol...
BioCentury | Nov 6, 2020
Targets & Mechanisms

Data Byte: newly identified host factors that regulate ACE2 expression

...and olfactory neurons showed high NRP1 expression.A University of Bristol...
...and Harvard German Center for Neurodegenerative Diseases University of Helsinki University of Bristol Angiotensin-converting...
BioCentury | Oct 14, 2019
Financial News

Mogrify raises $16M, outlines plans to advance cell therapy platform

...to co-develop its cell therapies. Mogrify already has one undisclosed partner. Parkwalk, 24Haymarket and the University of Bristol...
BioCentury | Aug 2, 2019
Company News

Aug. 1 Company Quick Takes: Nektar gains on breakthrough for NKTR-214; plus Adaptive's MRD test, Acadia, Vanda and more

...clonoSEQ test (Informal), clonoSEQ Assay (Informal) Acadia Pharmaceuticals Inc. Adaptive Biotechnologies Eton Pharmaceuticals Inc. Evotec SE Innovative Medicines Initiative (IMI) Nektar Therapeutics University of Bristol Vanda...
BioCentury | Apr 25, 2019
Emerging Company Profile

Cell Mogrify directly reprograms cells in vivo

...Medical Research Council Laboratory of Molecular Biology (MRC LMB) and professor of bioinformatics at the University of Bristol...
...collaborators: Duke NUS Medical School, Medical Research Council Laboratory of Molecular Biology (MRC-LMB), Monash University, University of Bristol...
...of Molecular Biology (MRC LMB), Cambridge, U.K. Mission Therapeutics Ltd., Cambridge, U.K. Riken, Wako, Japan University of Bristol...
BioCentury | Apr 5, 2019
Targets & Mechanisms

Breaking up Hippo to tame proliferation

...disruptors in any one of the binding pockets. Mark Bond, a senior lecturer at the University of Bristol...
...play in liver and kidney fibrosis. According to Mark Bond, a senior lecturer at the University of Bristol...
...Daix, France Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland University of Bristol...
BioCentury | Oct 13, 2018
Product Development

Trevena goes for MOR than morphine

...one score for oliceridine and did not specify the assay employed. Panelist Graeme Henderson, a University of Bristol...
...Brook University, Stony Brook, N.Y. Trevena Inc. (NASDAQ:TRVN), Chesterbrook, Pa. University of Arizona, Tucson, Ariz. University of Bristol...
BioCentury | Aug 31, 2018
Company News

Novo acquires Ziylo in quest for glucose-sensitive insulin

...insulin would likely reprice the insulin category, although it is a higher-risk project. Ziylo, a University of Bristol...
BioCentury | Aug 23, 2018
Product R&D

Sweet switch

...co-founder and former Ph.D. adviser, Anthony Davis. Davis, who is professor of supramolecular chemistry at University of Bristol...
...Kenilworth, N.J. Novo Nordisk A/S (NYSE:NVO; CSE:NOVO B), Bagsvaerd, Denmark Sanofi (NYSE:SNY; Euronext:SAN), Paris, France University of Bristol...
BioCentury | Aug 17, 2018
Company News

Novo acquires Ziylo in quest for glucose-sensitive insulin

...insulin would likely reprice the insulin category, although it is a higher-risk project. Ziylo, a University of Bristol...
Items per page:
1 - 10 of 41
BioCentury | Nov 19, 2020
Finance

Syncona enters kidney disease space with gene therapy newco Purespring

...the academic work of co-founder Moin Saleem, a professor of pediatric renal medicine at the University of Bristol...
BioCentury | Nov 6, 2020
Targets & Mechanisms

Data Byte: newly identified host factors that regulate ACE2 expression

...and olfactory neurons showed high NRP1 expression.A University of Bristol...
...and Harvard German Center for Neurodegenerative Diseases University of Helsinki University of Bristol Angiotensin-converting...
BioCentury | Oct 14, 2019
Financial News

Mogrify raises $16M, outlines plans to advance cell therapy platform

...to co-develop its cell therapies. Mogrify already has one undisclosed partner. Parkwalk, 24Haymarket and the University of Bristol...
BioCentury | Aug 2, 2019
Company News

Aug. 1 Company Quick Takes: Nektar gains on breakthrough for NKTR-214; plus Adaptive's MRD test, Acadia, Vanda and more

...clonoSEQ test (Informal), clonoSEQ Assay (Informal) Acadia Pharmaceuticals Inc. Adaptive Biotechnologies Eton Pharmaceuticals Inc. Evotec SE Innovative Medicines Initiative (IMI) Nektar Therapeutics University of Bristol Vanda...
BioCentury | Apr 25, 2019
Emerging Company Profile

Cell Mogrify directly reprograms cells in vivo

...Medical Research Council Laboratory of Molecular Biology (MRC LMB) and professor of bioinformatics at the University of Bristol...
...collaborators: Duke NUS Medical School, Medical Research Council Laboratory of Molecular Biology (MRC-LMB), Monash University, University of Bristol...
...of Molecular Biology (MRC LMB), Cambridge, U.K. Mission Therapeutics Ltd., Cambridge, U.K. Riken, Wako, Japan University of Bristol...
BioCentury | Apr 5, 2019
Targets & Mechanisms

Breaking up Hippo to tame proliferation

...disruptors in any one of the binding pockets. Mark Bond, a senior lecturer at the University of Bristol...
...play in liver and kidney fibrosis. According to Mark Bond, a senior lecturer at the University of Bristol...
...Daix, France Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland University of Bristol...
BioCentury | Oct 13, 2018
Product Development

Trevena goes for MOR than morphine

...one score for oliceridine and did not specify the assay employed. Panelist Graeme Henderson, a University of Bristol...
...Brook University, Stony Brook, N.Y. Trevena Inc. (NASDAQ:TRVN), Chesterbrook, Pa. University of Arizona, Tucson, Ariz. University of Bristol...
BioCentury | Aug 31, 2018
Company News

Novo acquires Ziylo in quest for glucose-sensitive insulin

...insulin would likely reprice the insulin category, although it is a higher-risk project. Ziylo, a University of Bristol...
BioCentury | Aug 23, 2018
Product R&D

Sweet switch

...co-founder and former Ph.D. adviser, Anthony Davis. Davis, who is professor of supramolecular chemistry at University of Bristol...
...Kenilworth, N.J. Novo Nordisk A/S (NYSE:NVO; CSE:NOVO B), Bagsvaerd, Denmark Sanofi (NYSE:SNY; Euronext:SAN), Paris, France University of Bristol...
BioCentury | Aug 17, 2018
Company News

Novo acquires Ziylo in quest for glucose-sensitive insulin

...insulin would likely reprice the insulin category, although it is a higher-risk project. Ziylo, a University of Bristol...
Items per page:
1 - 10 of 41